Postbaseline ALT elevations were greater than 3 times the ULN in 12 (0.8%) dalbavancin patients and 2 (0.2%) comparator treatment patients. Eight of 12 patients treated with dalbavancin and 1 of 2 patients treated with comparator drug had concomi- tant conditions that could elevate liver enzymes.